Modification of luminol-dependent chemiluminescence reactivity of peripheral blood leukocytes from patients with lymphoreticular tumor, solid cancer, or healthy blood donors by interferon-alpha.
Modification of luminol-dependent chemiluminescence reactivity of peripheral blood leukocytes from patients with lymphoreticular tumor, solid cancer, or healthy blood donors by interferon-alpha.
复制标题
干扰素-α 改变淋巴网状肿瘤、实体癌或健康献血者外周血白细胞的鲁米诺依赖性化学发光反应性。
DOI：
10.1089/jir.1987.7.1
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Blumenson,L
中科院分区：
文献类型：
--
作者：
Müller,S;Krasner,J;Ozer,H;Blumenson,L
用肝素化全血、肿瘤患者和健康献血员外周血白细胞研究了α-干扰素（rIFN-α2）对酵母多糖（Zymosan）或佛波酯（PMA）诱发的鲁米诺依赖性化学发光（CL）反应的调节作用。对确诊为慢性白血病、淋巴瘤或实体癌的患者进行rIFN-α 2治疗。与健康献血者的全血相比，患者组的全血中对酵母聚糖或PMA的CL发射增强。在两组中，肿瘤患者和健康献血者的右旋糖酐沉淀白细胞诱导的CL反应性没有差异。将患者或健康献血员的全血或分离的白细胞与0.001-1000 U/ml的rIFN-α 2共同孵育后再加入CL刺激剂，可增强CL对酵母多糖或PMA的反应性。rIFN-α 2本身不加其他试剂不刺激CL反应。因此，在患者人群的全血中观察到的对PMA或酵母聚糖的CL反应性增强似乎是由于IFN-输注导致的血清血液组分中存在干扰素，而不是由于肿瘤性疾病的其他症状或治疗，因为当分离的血液白细胞用于CL测定时，患者中的相对CL增强被消除。
The effect of interferon-α (rIFN-α2) on modulating the luminol-dependent chemiiuminescence (CL) response evoked by Zymosan or phorbol myristate acetate (PMA) has been studied in heparinized whole blood as well as isolated peripheral blood leukocytes derived from cancer patients and healthy blood donors. The cancer patients, diagnosed with chronic leukemia or lymphoma or solid cancer, were under rIFN-α2therapy. The CL emission to both Zymosan or PMA was enhanced in the whole blood of the patient's group in comparison to whole blood of healthy blood donors. CL reactivity induced in Dextran-sedimented leukocytes derived from neoplasia patients and healthy blood donors did not differ in the two groups. CL reactivity to Zymosan or PMA could be potentiated when whole blood samples or isolated leukocytes of patients or healthy blood donors were incubatedin vitrowith rIFN-α2in the range of 0.001-1000 U/ml prior to addition of CL-stimulating agents. rIFN-α2itself without adding further agents did not stimulate CL reactivity. Therefore, enhanced CL reactivity to PMA or Zymosan observed in the whole blood of the patients' population appears to be due to the presence of interferon in serum blood components as a consequence of IFN-infusion rather than to other symptoms or treatments of the neoplastic diseases, since the relative CL enhancement in patients is abrogated when isolated blood leukocytes are used for CL assay.